<--- Back to Details
First PageDocument Content
Genodermatoses / Von Hippel–Lindau disease / Von Hippel–Lindau tumor suppressor / Hemangioblastoma / Pheochromocytoma / Chromosome 3 / Genetic testing / Medicine / Health / Oncology
Date: 2012-05-11 07:09:04
Genodermatoses
Von Hippel–Lindau disease
Von Hippel–Lindau tumor suppressor
Hemangioblastoma
Pheochromocytoma
Chromosome 3
Genetic testing
Medicine
Health
Oncology

VHL Family Forum Volume 6, Number 1 ISSN[removed]Childbearing Choices

Add to Reading List

Source URL: vhl.org

Download Document from Source Website

File Size: 777,20 KB

Share Document on Facebook

Similar Documents

Clinical Neutron Therapy System Reference Manual Jonathan Jacky1 Ruedi Risler Radiation Oncology, Box

Clinical Neutron Therapy System Reference Manual Jonathan Jacky1 Ruedi Risler Radiation Oncology, Box

DocID: 1xVse - View Document

Formal Development of a Graphical User Interface for a Radiation Therapy Machine Jonathan Jacky  Jonathan Unger Radiation Oncology Department RC-08 University of Washington

Formal Development of a Graphical User Interface for a Radiation Therapy Machine Jonathan Jacky  Jonathan Unger Radiation Oncology Department RC-08 University of Washington

DocID: 1xViy - View Document

Experience with Z Developing a Control Program for a Radiation Therapy Machine Jonathan Jacky , Jonathan Unger, Michael Patrick and Ruedi Risler Radiation Oncology Box

Experience with Z Developing a Control Program for a Radiation Therapy Machine Jonathan Jacky , Jonathan Unger, Michael Patrick and Ruedi Risler Radiation Oncology Box

DocID: 1xV2d - View Document

Formal Specication and Development of Control System Input/Output Jonathan Jacky Radiation Oncology Department RC-08 University of Washington

Formal Speci cation and Development of Control System Input/Output Jonathan Jacky Radiation Oncology Department RC-08 University of Washington

DocID: 1xUvZ - View Document

European Society for Medical Oncology (ESMOCongress Roche Analyst Audio Webcast Monday, 22 October 2018 Welcome Daniel O’Day, CEO Roche Pharmaceuticals

European Society for Medical Oncology (ESMOCongress Roche Analyst Audio Webcast Monday, 22 October 2018 Welcome Daniel O’Day, CEO Roche Pharmaceuticals

DocID: 1xTgE - View Document